NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

... and anyone who does not acknowledge that crossing over to a known active treatment, that is still considered experimental until proper measures to validate it are accepted and approved through “the process”, is deliberately misinterpreting the data as if the active treatment is not really active and especially effective in mesenchymal signature non temozolomide using crossover patients. The exceptions rule to adequate and well controlled trials allowed for proof to be presented that inadequate measures needed to be replaced with new ones. That includes the use of ECAs that are properly vetted and accepted under peer review which Dr. Linda Liau began the process of in presentations to peers before May 10th, 2022. That was continued on that day with a top line data presentation with the use of the ECA measures mentioned in prior discussions then those ECAs were formally peer reviewed and accepted by JAMA Oncology. This is proof of a general validation of those measures by . THAT is your big problem that Dr. Bala continually reminds you of. The ECAs have been peer reviewed and accepted as valid by the peer community. That those with an agenda would oppose this is to be expected as they are protecting their own interests. The vast majority of peers are not aligned with them or the interests that they represent but rather with the patients. Even the investment community recognizes the change that is coming and the failure of NVCR to live up to patient expectations while Sawston builds a waiting list of patients wanting a real chance at a cure. Best wishes.